Business Wire

Lundbytunneln i Göteborg förbättrar säkerheten med Kapsch TrafficCom

Dela

Trafikverket har tilldelat Kapsch TrafficCom (Kapsch) kontraktet för uppgraderingen av Lundbytunneln i Göteborg. För att förbättra säkerhet och trafikflöde kommer kontroll- och övervakningssystemet att moderniseras genom att implementera ett nytt CCTV-system med automatisk incidentdetektering.

Lundbytunneln på Hisingen i Göteborg är cirka 2 km lång och består av två parallella, tvåfiliga tunnelrör. Den invigdes 1998 och byggdes för att förbättra miljön för invånarna i området och trafikflödet längs den kraftigt använda genomfartsvägen. Det är den längsta tunneln i västra Sverige. Eftersom tunnlar utgör de mest sårbara platserna för vägar, fick Kapsch uppdraget att implementera ett nytt Avancerat Trafikövervaknings- och Trafikledningssystem (Advanced Traffic Management System, ATMS).

Det uppgraderade systemet samlar in trafikdata i realtid och levererar datan till övervakningscentraler, vilket gör det möjligt för operatörer att upptäcka och åtgärda incidenter såsom trafikstopp, nödsituationer, etc. Informationen kan sedan snabbt spridas till bilisterna i och omkring tunneln så att de uppmärksammas på incidenten samt kan fatta beslut om vidare resplan. För det nya CCTV-systemet kommer alla kameror i tunneln (cirka 80 enheter) att ersättas. Systemet för automatisk incidentdetektering utvidgas med nya funktioner relaterade till fotgängare, tappad last och rökutveckling.

”Vi har installerat våra innovativa system i tunnlar, broar, städer och vägar över hela världen, men detta blir det första ATMS-projektet för Kapsch i Sverige. Detta innebär ytterligare framgång och engagemang för Kapsch på den skandinaviska marknaden, där vi redan har visat oss vara en pålitlig partner för andra typer av intelligenta transport- och trafiksystem”, säger Mikael Hejel som är försäljningsansvarig för Norden.

Kapsch TrafficCom är leverantör av intelligenta transport- och trafiksystem inom områdena automatisk avgiftsupptagning, trafikövervakning och trafikledning, smart urban mobilitet, trafiksäkerhet och anslutna fordon. Som “one-stop-shop”-leverantör erbjuder Kapsch TrafficCom helhetslösningar som täcker hela kundens värdekedja, från komponenter och design till implementering och drift av system. Företaget har implementerat sex rikstäckande system för automatiska vägtullar och har referenser i mer än 50 länder runt om i världen, bland dem automatiska avgiftsupptagningslösningar för Golden Gate Bridge och Sydney Harbour Bridge samt lösningar för trafikövervakning och trafikledning i städer som Buenos Aires och Madrid.

För ytterligare information: www.kapsch.net/ktc?lang=en-us

Följ oss på https://twitter.com/kapschnet och https://www.linkedin.com/company/kapsch-trafficcom-ag/

Contact information

Försäljningsansvarig Norden
Mikael Hejel
Mobil +46 768 79 44 45
mikael.hejel@kapsch.net

Kapsch TrafficCom AB | Bataljonsgatan 10 | Box 1063 | 55110 Jönköping | Sweden

Presskontakt
Markus Karner
Telefon +43 50 811 1705
markus.karner@kapsch.net

Om

Business Wire
Business Wire



Följ Business Wire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från Business Wire

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum